Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06359860RecruitingPhase 1/Phase 2
Testing ST-1898 for advanced acral melanoma
This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.
BeijingAges 18 years+ - NCT06363591Recruiting
One vs two surgeries for thin melanoma
This trial compares having one surgery to remove extra skin around a thin melanoma versus the standard two-step approach (biopsy first, then a wider excision later). It aims to see if one surgery is just as safe and reduces the number of procedures.
GothenburgAges 18 years+ - NCT06400550Recruiting
Melanoma metabolism and spread risk study
This study looks at how the body's metabolism might affect the spread of melanoma. Researchers want to see if certain metabolic traits in people with melanoma are linked to a higher risk of the cancer spreading.
Dallas, TexasAges 18 years+ - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06472661RecruitingEarly Phase 1
Focused ultrasound plus drug injection for melanoma before surgery
This trial tests a new combination approach for advanced melanoma that is planned for surgical removal. It uses focused ultrasound to heat the tumor, followed by an injection of an experimental immune-stimulating drug (polyICLC), while you continue your standard immunotherapy. The goal is to make the immune system attack the cancer more effectively.
Charlottesville, VirginiaAges 18 years+ - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06519266RecruitingPhase 3
Liver treatment with immunotherapy for uveal melanoma that spread to the liver
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
GothenburgAges 18 years+ - NCT06536257Recruiting
Personalized immunotherapy prediction for melanoma and other cancers
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Sydney, New South WalesAges 18 years+ - NCT06545682RecruitingPhase 1
Study of alpelisib and pembrolizumab for advanced breast cancer or melanoma
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Houston, TexasAges 18 years+ - NCT06548789RecruitingPhase 2
Immunotherapy plus prebiotic foods for melanoma before surgery
This study tests if eating certain prebiotic foods while receiving immunotherapy before melanoma surgery can boost your immune system and improve treatment response. Participants eat study-provided foods and receive standard immunotherapy (ipilimumab with or without nivolumab, or nivolumab with or without relatlimab).
Houston, TexasAges 18 years+ - NCT06550674Recruiting
Genetic study for uveal melanoma risk
This study looks for new inherited genes linked to uveal melanoma (an eye cancer). If you have this cancer and don't already have a known genetic cause, you may be able to help find new genes that affect cancer risk.
Clermont-Ferrand, Puy-de-DômeAges 18 years+ - NCT06560905RecruitingPhase 2
PSMA-PET scan before melanoma surgery
This trial tests if a special scan (PSMA-PET) can help plan surgery for melanoma that has spread to lymph nodes. It may help doctors remove all cancer more accurately.
LondonAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT07086105RecruitingPhase 1
Study of Adze1.C for advanced melanoma
This trial tests a new injected virus therapy (Adze1.C) for people with advanced melanoma that hasn't responded to other treatments. The virus is designed to attack tumors directly and may help your immune system fight the cancer.
Southport, QueenslandAges 18 years+ - NCT06602648Recruiting
Melanoma care study for young patients
This study aims to find better ways to treat melanoma in children, teenagers, and young adults. It may help improve care for patients under 30 years old with certain types of skin growths.
Florence, ItalyAges Up to 30 years - NCT06621810Recruiting
AI for melanoma detection in children and young adults
This study uses artificial intelligence to help detect melanoma (a type of skin cancer) and predict risk in children, teens, and young adults. Researchers want to see if AI can spot melanoma early and assess risk better.
TübingenAges Any age - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT06630611RecruitingPhase 2
A new immune cell therapy for melanoma, lung, and cervical cancer
This trial tests a new way to boost your immune cells after they are collected from your tumor and grown in a lab. Instead of high-dose IL-2, you would get a modified version called ANV419, which may have fewer side effects.
BarcelonaAges 18 years+ - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT06651151RecruitingPhase 2
Neoadjuvant LTX-315 plus pembrolizumab for resectable melanoma
This trial tests a combination of two drugs (LTX-315 and pembrolizumab) given before surgery to shrink melanoma that is stage III or IV (M1a) and can be removed. The goal is to see if this approach works better than surgery alone.
Oslo, OsloAges 18 years+ - NCT06697301RecruitingPhase 2/Phase 3
New drug with pembrolizumab for advanced melanoma
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Chandler, ArizonaAges 18 years+ - NCT06712927RecruitingPhase 2
Three-drug immunotherapy for melanoma brain metastases
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT06727630RecruitingPhase 1/Phase 2
A study of PRJ1-3024 for advanced or spreading melanoma
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06753136Recruiting
Electrochemotherapy for internal organ tumors
This trial tests a treatment called electrochemotherapy for tumors in internal organs (like the liver or pancreas) when standard treatments are no longer possible. It uses a drug called bleomycin plus electric pulses to target cancer cells.
PadovaAges 18–99
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 465 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.